Notice for belzutifan (Merck Sharp & Dohme (Australia) Pty Ltd)
Active ingredients
belzutifan
Date of review outcome
Lapse date
Type
Provisional determination
Dosage form(s)
Immediate-release tablet
Therapeutic area
Oncology